Molecular Subtypes and Treatment Modalities in Breast Cancer in a Brazilian Military Hospital: An Observational Study
4 affiliations
- 1Brasília Area Military Hospital (HMAB) Brasília Brazil
- 2School of Medicine University of Brasília (UnB) Brasília Brazil unb.br
- 3Laboratory of Cancer Molecular Pathology Faculty of Health Sciences Universtiy of Brasilia (UnB) Brasília Brazil
- 4Center for Molecular Biotechnology (C-Biotech) Universtiy of Brasilia (UnB) Brasília Brazil
Abstract
Breast cancer is a global public health concern and the most common malignancy in women, with a lifetime risk of 12.5%. It is also the most frequently diagnosed cancer, accounting for 11.6% of all cases. This study is aimed at describing the clinical, anatomopathological, and sociodemographic profile of women diagnosed with breast cancer at a public military hospital in Brazil, and evaluating the association between molecular subtypes and the type of treatment received. This was an observational, cross‐sectional, and quantitative study. Data were extracted from the hospital′s electronic medical records (AGHUse platform) in 2022 and 2025, involving a total of 102 women. Most cases were diagnosed at clinical Stage II (49.0%). Regarding molecular classification, the most prevalent subtype was Luminal B (47.1%), followed by Luminal A (18.6%), HER2‐enriched luminal (16.7%), triple negative (12.8%), and HER2‐enriched nonluminal (4.9%). A total of 54.9% of the tumors had histological Grade 2. Most patients (71.6%) did not present metastases, whereas a minority did (28.4%). Treatment decisions were guided by molecular subtypes, with triple negative and HER2‐enriched subtypes more frequently receiving neoadjuvant or palliative treatment and luminal subtypes predominantly treated with adjuvant therapy; no statistically significant association was found between individual molecular subtypes and the overall type of treatment received, which is likely attributable to the limited statistical power resulting from the small sample size within the neoadjuvant subgroup (n = 36). The total cohort for neoadjuvant analysis consisted of 36 patients, with a global pathological complete response (pCR) rate of 47.2% (n = 17). Within the residual disease group (n = 19), qualitative stratification revealed that 73.7% (n = 14) achieved a partial response (pPR), whereas 26.3% (n = 5) presented a minimal response. Although the global association between molecular subtypes and pathological response (pCR vs. RD) did not reach statistical significance (p = 0.2831), a subgroup analysis comparing aggressive phenotypes (triple negative and HER2‐enriched) against luminal phenotypes (Luminal A and B) was evaluated (p = 0.169; OR = 3.61; 95% CI: 0.86–15.20). Aggressive subtypes demonstrated a clinically higher rate of pCR (59.1% vs. 28.6%), supporting biological aggressiveness as a driver of chemosensitivity in this cohort. These results contribute to clinical decision‐making and a better understanding of the disease profile in women treated in military hospitals. Moreover, it highlights the need for better response prediction markers for pathological response.
Related
- Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
- Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis.
- Examining the Relationship Between Perceived Social Satisfaction, Depression, and Anxiety for People With Multiple Sclerosis Participating in Group Treatment Modalities
- Identification of CRF-related molecular subtypes and a prognostic CRRS model in glioma: insights into immunotherapy response prediction and candidate biomarkers
- Management of Grade II osteoarthritis (Azhal kilvayu) utilizing Siddha internal and external treatment modalities (Varmam and Thokkanam): A case report.
BibTeX
@article{silva2026molecular,
title = {{Molecular Subtypes and Treatment Modalities in Breast Cancer in a Brazilian Military Hospital: An Observational Study}},
author = {Larissa Fernanda Campos Moreira da Silva and Fabiana Pirani Carneiro and Andrea Barretto Motoyama},
journal = {BioMed Research International},
year = {2026},
month = oct,
doi = {10.1155/bmri/4549789},
url = {https://doi.org/10.1155/bmri/4549789},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Molecular Subtypes and Treatment Modalities in Breast Cancer in a Brazilian Military Hospital: An Observational Study
AU - Larissa Fernanda Campos Moreira da Silva
AU - Fabiana Pirani Carneiro
AU - Andrea Barretto Motoyama
PY - 2026
DA - 2026/10/29
JO - BioMed Research International
DO - 10.1155/bmri/4549789
UR - https://doi.org/10.1155/bmri/4549789
AB - Breast cancer is a global public health concern and the most common malignancy in women, with a lifetime risk of 12.5%. It is also the most frequently diagnosed cancer, accounting for 11.6% of all cases. This study is aimed at describing the clinical, anatomopathological, and sociodemographic profile of women diagnosed with breast cancer at a public military hospital in Brazil, and evaluating the association between molecular subtypes and the type of treatment received. This was an observational, cross‐sectional, and quantitative study. Data were extracted from the hospital′s electronic medical records (AGHUse platform) in 2022 and 2025, involving a total of 102 women. Most cases were diagnosed at clinical Stage II (49.0%). Regarding molecular classification, the most prevalent subtype was Luminal B (47.1%), followed by Luminal A (18.6%), HER2‐enriched luminal (16.7%), triple negative (12.8%), and HER2‐enriched nonluminal (4.9%). A total of 54.9% of the tumors had histological Grade 2. Most patients (71.6%) did not present metastases, whereas a minority did (28.4%). Treatment decisions were guided by molecular subtypes, with triple negative and HER2‐enriched subtypes more frequently receiving neoadjuvant or palliative treatment and luminal subtypes predominantly treated with adjuvant therapy; no statistically significant association was found between individual molecular subtypes and the overall type of treatment received, which is likely attributable to the limited statistical power resulting from the small sample size within the neoadjuvant subgroup (n = 36). The total cohort for neoadjuvant analysis consisted of 36 patients, with a global pathological complete response (pCR) rate of 47.2% (n = 17). Within the residual disease group (n = 19), qualitative stratification revealed that 73.7% (n = 14) achieved a partial response (pPR), whereas 26.3% (n = 5) presented a minimal response. Although the global association between molecular subtypes and pathological response (pCR vs. RD) did not reach statistical significance (p = 0.2831), a subgroup analysis comparing aggressive phenotypes (triple negative and HER2‐enriched) against luminal phenotypes (Luminal A and B) was evaluated (p = 0.169; OR = 3.61; 95% CI: 0.86–15.20). Aggressive subtypes demonstrated a clinically higher rate of pCR (59.1% vs. 28.6%), supporting biological aggressiveness as a driver of chemosensitivity in this cohort. These results contribute to clinical decision‐making and a better understanding of the disease profile in women treated in military hospitals. Moreover, it highlights the need for better response prediction markers for pathological response.
SN - 2314-6133
SN - 2314-6141
ER -